These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19317360)

  • 21. Severe sepsis and septic shock: review of the literature and emergency department management guidelines.
    Nguyen HB; Rivers EP; Abrahamian FM; Moran GJ; Abraham E; Trzeciak S; Huang DT; Osborn T; Stevens D; Talan DA;
    Ann Emerg Med; 2006 Jul; 48(1):28-54. PubMed ID: 16781920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjunctive therapies for severe sepsis.
    Wittebole X; Collienne C; Castanares-Zapatero D; Laterre PF
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S34-8. PubMed ID: 18715758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of treatments for severe sepsis: data from the bundle implementation programs.
    Ferrer R; Artigas A
    Minerva Anestesiol; 2011 Mar; 77(3):360-5. PubMed ID: 21441890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of sepsis during the early "golden hours".
    Raghavan M; Marik PE
    J Emerg Med; 2006 Aug; 31(2):185-99. PubMed ID: 17044583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New treatment strategies for severe sepsis and septic shock.
    Patel GP; Gurka DP; Balk RA
    Curr Opin Crit Care; 2003 Oct; 9(5):390-6. PubMed ID: 14508152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated).
    Critical Care Society of South Africa Working Group
    S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374
    [No Abstract]   [Full Text] [Related]  

  • 27. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
    Crum NF; Groff HL; Parrish JS; Ring W
    Clin Infect Dis; 2004 Dec; 39(11):e122-3. PubMed ID: 15578351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sepsis strategies: an ICU package?
    Ruffell AJ
    Nurs Crit Care; 2004; 9(6):257-63. PubMed ID: 15575634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Severe sepsis treated with activated protein C].
    Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drotrecogin alpha (activated) in neonatal septic shock.
    Frommhold D; Birle A; Linderkamp O; Zilow E; Pöschl J
    Scand J Infect Dis; 2005; 37(4):306-8. PubMed ID: 15804668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of septic shock.
    Vincent JL; de Carvalho FB; De Backer D
    Ann Med; 2002; 34(7-8):606-13. PubMed ID: 12553501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis.
    Jamdar S; Siriwardena AK
    Crit Care; 2005 Aug; 9(4):321-2. PubMed ID: 16137370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of sepsis in the surgical intensive care unit.
    Carney DE; Matsushima K; Frankel HL
    Isr Med Assoc J; 2011 Nov; 13(11):694-9. PubMed ID: 22279706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 39. Advances in the management of sepsis: the randomised controlled trials behind the Surviving Sepsis Campaign recommendations.
    Poulton B
    Int J Antimicrob Agents; 2006 Feb; 27(2):97-101. PubMed ID: 16417989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sepsis and septic shock: inching forwards.
    Cohen J
    Clin Med (Lond); 2009 Jun; 9(3):256-7. PubMed ID: 19634390
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.